ZenagemBio is developing a new generation of small molecule therapeutics for solid tumors by targeting the biology that drives tumor growth and immune evasion.
Our proprietary ZIP™ Platform enables the discovery of previously inaccessible drug targets and the design of safer, more selective small molecules that inhibit tumor growth while reprogramming the tumor microenvironment to support durable anti-tumor responses. By uncovering novel mechanisms of disease, we are expanding the universe of druggable targets and creating new therapeutic opportunities where conventional approaches have fallen short.
Built on a powerful chemoproteomics platform, ZIP™ reveals functional protein biology that cannot be detected by traditional target discovery methods.
ZenagemBio's lead development program is focused on glioblastoma (GBM), one of the most aggressive and treatment-resistant forms of brain cancer, with the broader vision of applying our platform across multiple solid tumor indications.
Our mission is to transform cancer treatment by discovering first-in-class medicines that are both more effective and safer for patients.

ZenagemBio

Org chart

Teams

Offices

ZenagemBio

Org chart

Teams

Offices

Related companies